Association of Cystatin C with Adverse Outcomes

作者: Magdalena Madero , Mark J Sarnak

DOI: 10.1097/MNH.0B013E328326F3DD

关键词:

摘要: PURPOSE OF REVIEW To discuss recent studies which have evaluated determinants of cystatin C and to focus on the relationship with mortality, cardiovascular disease (CVD), noncardiovascular outcomes. RECENT FINDINGS In Chronic Kidney Disease Epidemiology Study was associated demographic characteristics independent measured glomerular filtration rate (GFR), although this a smaller extent than creatinine. patients established chronic kidney (CKD), strongly inversely correlated GFR, suggesting that may other determinants, it is primarily measure function. Several cohort studies, particularly in older adults, now demonstrated linearly CVD non-CVD outcomes, whereas creatinine risk individuals more advanced disease. A study has also shown changes function as ascertained by C, even within relatively normal range, are subsequent all-cause mortality among adults. SUMMARY Cystatin appears capture an association mild increased Future should evaluate whether can improve medical decision-making lead favorable patient

参考文章(45)
Linda F. Fried, Jung Sun Lee, Michael Shlipak, Glenn M. Chertow, Christie Green, Jingzhong Ding, Tamara Harris, Anne B. Newman, , Chronic kidney disease and functional limitation in older people: health, aging and body composition study. Journal of the American Geriatrics Society. ,vol. 54, pp. 750- 756 ,(2006) , 10.1111/J.1532-5415.2006.00727.X
Stephan A Kaeser, Martin C Herzig, Janaky Coomaraswamy, Ellen Kilger, Maj-Linda Selenica, David T Winkler, Matthias Staufenbiel, Efrat Levy, Anders Grubb, Mathias Jucker, Cystatin C modulates cerebral beta-amyloidosis. Nature Genetics. ,vol. 39, pp. 1437- 1439 ,(2007) , 10.1038/NG.2007.23
Lorenz Risch, Roberto Herklotz, Alfred Blumberg, Andreas R Huber, EFFECTS OF GLUCOCORTICOID IMMUNOSUPPRESSION ON SERUM CYSTATIN C CONCENTRATIONS IN RENAL TRANSPLANT PATIENTS Clinical Chemistry. ,vol. 47, pp. 2055- 2059 ,(2001) , 10.1093/CLINCHEM/47.11.2055
Michael G. Shlipak, Cystatin C: research priorities targeted to clinical decision making. American Journal of Kidney Diseases. ,vol. 51, pp. 358- 361 ,(2008) , 10.1053/J.AJKD.2008.01.002
Bryan Kestenbaum, Kyle D. Rudser, Ian H. de Boer, Carmen A. Peralta, Linda F. Fried, Michael G. Shlipak, Walter Palmas, Catherine Stehman-Breen, David S. Siscovick, Differences in kidney function and incident hypertension: The multi-ethnic study of atherosclerosis Annals of Internal Medicine. ,vol. 148, pp. 501- 508 ,(2008) , 10.7326/0003-4819-148-7-200804010-00006
J. Arpegård, J. Östergren, U. de Faire, L.-O. Hansson, P. Svensson, Cystatin C--a marker of peripheral atherosclerotic disease? Atherosclerosis. ,vol. 199, pp. 397- 401 ,(2008) , 10.1016/J.ATHEROSCLEROSIS.2007.11.025
Kristine E Ensrud, Li-Ying Lui, Brent C Taylor, Areef Ishani, Michael G Shlipak, Katie L Stone, Jane A Cauley, Sophie A Jamal, Diana M Antoniucci, Steven R Cummings, Study of Osteoporotic Fractures Research Group, None, Renal function and risk of hip and vertebral fractures in older women. JAMA Internal Medicine. ,vol. 167, pp. 133- 139 ,(2007) , 10.1001/ARCHINTE.167.2.133
Kristine Yaffe, Karla Lindquist, Michael G. Shlipak, Eleanor Simonsick, Linda Fried, Caterina Rosano, Suzanne Satterfield, Hal Atkinson, B. Gwen Windham, Manjula Kurella-Tamura, , Cystatin C as a marker of cognitive function in elders: findings from the health ABC study. Annals of Neurology. ,vol. 63, pp. 798- 802 ,(2008) , 10.1002/ANA.21383
M. C. Odden, G. M. Chertow, L. F. Fried, A. B. Newman, S. Connelly, S. Angleman, T. B. Harris, E. M. Simonsick, M. G. Shlipak, , Cystatin C and Measures of Physical Function in Elderly Adults The Health, Aging, and Body Composition (HABC) Study American Journal of Epidemiology. ,vol. 164, pp. 1180- 1189 ,(2006) , 10.1093/AJE/KWJ333